Rheumatology International

, Volume 38, Issue 5, pp 879–885 | Cite as

Canakinumab treatment in children with familial Mediterranean fever: report from a single center

  • Fatma Yazılıtaş
  • Özlem Aydoğ
  • Sare Gülfem Özlü
  • Evrim Kargın Çakıcı
  • Tülin Güngör
  • Fehime Kara Eroğlu
  • Gökçe Gür
  • Mehmet Bülbül
Observational Research


Familial Mediterranean fever (FMF), the most common hereditary autoinflammatory disorder is characterized by recurrent episodes of fever, serositis, arthritis. The major long-term result is amyloidosis. Colchicine remains the principle of the treatment; it not only prevents the acute attacks but also prevents the long-term complications such as amyloidosis; 5–10% of the patients are unresponsive to treatment. Recently new therapeutic options as anti-interleukin 1 agents are successfully used for the patients who do not respond to colchicine treatment. In this study, we retrospectively evaluated 11 pediatric colchicine-resistant FMF patients who were treated with canakinumab. Three of the patients had amyloidosis and two had uveitis. Based on our results, we suggest that canakinumab may be a safe and effective therapy in patients who are resistant to colchicine and even in the patients with amyloidosis. We also suggest that canakinumab might be a safe option for the patients with uveitis.


Amyloidosis Canakinumab Childhood Familial Mediterranean fever Uveitis 


Author contributions

Study conception and design: FY and OA. Acquisition of data: contribution of all authors. Analysis and interpretation of data: FY and SGÖ. Drafting of manuscript: FY and MB. Critical revision: contribution of all authors.


No funding.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.


  1. 1.
    Ozen S, Bilginer Y (2014) A clinical guide to autoinflammatory diseases: familial Mediterranean fever and next-of-kin. Nat Rev Rheumatol 10(3):135–147. CrossRefPubMedGoogle Scholar
  2. 2.
    Sarı I, Birlik M, Kasifoğlu T (2014) Familial Mediterranean fever: an updated review. Eur J Rheumatol 1(1):21–33CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    French FMF Consortium (1997) A candidate gene for familial Mediterranean fever. Nat Genet 17(1):25–31CrossRefGoogle Scholar
  4. 4.
    The International FMF Consortium (1997) Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell 90(4):797–807CrossRefGoogle Scholar
  5. 5.
    Chae JJ, Wood G, Richard K, Jaffe H, Colburn NT, Masters SL et al (2008) The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-kappaB through its N-terminal fragment. Blood 1 112(5):1794–1803. CrossRefGoogle Scholar
  6. 6.
    Dinarello CA (1996) Biologic basis for interleukin-1 in disease. Blood 15(6):2095–2147 (2187)Google Scholar
  7. 7.
    Bozkurt Y, Demir A, Erman B, Gül A (2015) Unified modeling of familial Mediterranean fever and cryopyrin associated periodic syndromes. Comput Math Methods Med 2015:893507. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chae JJ, Aksentijevich I, Kastner DL (2009) Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. Br J Haematol 146(5):467–478. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wang DQH, Bonfrate L, de Bari O, Wang TY, Portincasa P (2014) Familial Mediterranean fever: from pathogenesis to treatment. J Genet Syndr Gene Ther 5:248. Google Scholar
  10. 10.
    Brough D, Rothwell NJ (2007) Caspase-1-dependent processing of pro-interleukin-1 beta is cytosolic and precedes cell death. J Cell Sci 1 120 (Pt 5):772–781CrossRefGoogle Scholar
  11. 11.
    Stojanov S, Kastner DL (2005) Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 17(5):586–599CrossRefPubMedGoogle Scholar
  12. 12.
    Grattagliano I, Bonfrate L, Ruggiero V, Scaccianoce G, Palasciano G, Portincasa P (2014) Novel therapeutics for the treatment of familial mediterranean fever: from colchicine to biologics. Clin Pharmacol Ther 95(1):89–97CrossRefPubMedGoogle Scholar
  13. 13.
    Bilginer Y, Akpolat T, Ozen S (2011) Renal amyloidosis in children. Pediatr Nephrol 26(8):1215–1227. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Duzova A, Bakkaloglu A, Besbas N, Topaloglu R, Ozen S, Ozaltin F et al (2003) Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. Clin Exp Rheum 21(4):509–514Google Scholar
  15. 15.
    Kuijk LM, Govers AM, Frenkel J, Hofhuis WJ (2007) Effective treatment of a colchicineresistant familial Mediterranean fever patient with anakinra. Ann Rheum Dis 66(11):1545–1546CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Meinzer U, Quartier P, Alexandra JF, Hentgen V, Retornaz F, Koné-Paut I (2011) Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 41(2):265–271. CrossRefPubMedGoogle Scholar
  17. 17.
    Eroglu FK, Beşbaş N, Topaloglu R, Ozen S (2015) Treatment of colchicine-resistant Familial Mediterranean fever in children and adolescents. Rheumatol Int 35(10):1733–1737. CrossRefPubMedGoogle Scholar
  18. 18.
    Haviv R, Hashkes PJ (2016) Canakinumab investigated for treating familial Mediterranean fever. Expert Opin Biol Ther 16(11):1425–1434CrossRefPubMedGoogle Scholar
  19. 19.
    Mitroulis I, Skendros P, Oikonomou A, Tzioufas AG, Ritis K (2011) The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and long standing destructive arthritis. Ann Rheum Dis 70(7):1347–1348. CrossRefPubMedGoogle Scholar
  20. 20.
    Özçakar ZB, Özdel S, Yılmaz S, Kurt-Şükür ED, Ekim M, Yalçınkaya F (2016) Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis. Clin Rheumatol 35(2):441–446. CrossRefPubMedGoogle Scholar
  21. 21.
    Sozeri B, Gulez N, Ergin M, Serdaroglu E (2016) The experience of canakinumab in renal amyloidosis secondary to familial Mediterranean fever. Mol Cell Pediatr 3(1):33. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Topaloglu R, Batu ED, Orhan D, Ozen S, Besbas N (2016) Anti-interleukin 1 treatment in secondary amyloidosis associated with autoinflammatory diseases. Pediatr Nephrol 31(4):633–640. CrossRefPubMedGoogle Scholar
  23. 23.
    Scarpioni R, Rigante D, Cantarini L, Ricardi M, Albertazzi V, Melfa L et al (2015) Renal involvement in secondary amyloidosis of Muckle–Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab. Clin Rheumatol 34(7):1311–1316. CrossRefPubMedGoogle Scholar
  24. 24.
    Livneh A, Langevitz P, Zemer D, Zaks N, Kees S, Lidar T et al (1997) Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 40(10):1879–1885CrossRefPubMedGoogle Scholar
  25. 25.
    Ozen S, Kone-Paut I, Gül A (2017) Colchicine resistance and intolerance in familial mediterranean fever: definition, causes, and alternative treatments. Semin Arthritis Rheum 47(1):115–120. CrossRefPubMedGoogle Scholar
  26. 26.
    Lidar M, Scherrmann JM, Shinar Y, Chetrit A, Niel E, Gershoni-Baruch R et al (2004) Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. Semin Arthritis Rheum 33(4):273–282CrossRefPubMedGoogle Scholar
  27. 27.
    Ozen S, Demirkaya E, Duzova A, Erdogan O, Erken E, Gul A et al (2014) FMF50: a score for assessing outcome in familial Mediterranean fever. FMF Arthritis Vasculitis and Orphan disease Research in pediatric rheumatology (FAVOR) and Turkish FMF study group. Ann Rheum Dis 73(5):897–901. CrossRefPubMedGoogle Scholar
  28. 28.
    Cakar N, Yalçinkaya F, Ozkaya N, Tekin M, Akar N, Koçak H et al (2001) Familial Mediterranean fever (FMF)-associated amyloidosis in childhood. Clinical features, course and outcome. Clin Exp Rheumatol 19(5 Suppl 24):S63–S67PubMedGoogle Scholar
  29. 29.
    Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J (1986) Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med 314(16):1001–1005. CrossRefPubMedGoogle Scholar
  30. 30.
    Shohat M (2000) In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Mefford HC, Stephens K, Amemiya A, Ledbetter N (eds) GeneReviews® (internet), 1993–2017. University of Washington, Seattle (updated 15 Dec 2016)Google Scholar
  31. 31.
    Soylemezoglu O, Arga M, Fidan K, Gonen S, Emeksiz HC, Hasanoglu E et al (2010) Unresponsiveness to colchicine therapy in patients with familial Mediterranean fever homozygous for the M694V mutation. J Rheumatol 37(1):182–189. CrossRefPubMedGoogle Scholar
  32. 32.
    Ozen S, Demirkaya E, Erer B, Livneh A, Ben-Chetrit E, Giancane G et al (2016) EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis 75(4):644–651. CrossRefPubMedGoogle Scholar
  33. 33.
    Omenetti A, Carta S, Delfino L, Martini A, Gattorno M, Rubartelli A (2014) Increased NLRP3-dependent interleukin 1β secretion in patients with familial Mediterranean fever: correlation with MEFV genotype. Ann Rheum Dis 73(2):462–469. CrossRefPubMedGoogle Scholar
  34. 34.
    Yalcinkaya F, Ozcakar ZB, Tanyildiz M, Elhan AH (2011) Familial Mediterranean fever in small children in Turkey. Clin Exp Rheumatol 29(4 Suppl 67):S87–S90PubMedGoogle Scholar
  35. 35.
    Bilginer Y, Ayaz NA, Ozen S (2010) Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 29(2):209–210. CrossRefPubMedGoogle Scholar
  36. 36.
    Başaran Ö, Uncu N, Çelikel BA, Taktak A, Gür G, Cakar N (2015) Interleukin-1 targeting treatment in familial Mediterranean fever: an experience of pediatric patients. Mod Rheumatol 25(4):621–624. CrossRefPubMedGoogle Scholar
  37. 37.
    Ozdogan H, Ugurlu S (2017) Canakinumab for the treatment of familial Mediterranean fever. Expert Rev Clin Immunol 13(5):393–404. CrossRefPubMedGoogle Scholar
  38. 38.
    Brik R, Butbul-Aviel Y, Lubin S, Ben Dayan E, Rachmilewitz-Minei T, Tseng L et al (2014) Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study (Hoboken, NJ). Arthritis Rheumatol (Hoboken NJ) 66(11):3241–3243. CrossRefGoogle Scholar
  39. 39.
    Ozkan S, Atas B (2017) Canakinumab treatment in four children with colchicine resistant familial mediterranean fever. J Pak Med Assoc 67(6):945–947PubMedGoogle Scholar
  40. 40.
    Gül A, Ozdogan H, Erer B, Ugurlu S, Kasapcopur O, Davis N, Sevgi S. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther 17:243.
  41. 41.
    Salehzadeh F, Yasrebi O, Hosseini Khotbesara M, Hosseini Khotbesara M (2014) Idiopathic uveitis and familial Mediterranean fever: is there any relationship? Autoimmune Dis 2014:238931. PubMedPubMedCentralGoogle Scholar
  42. 42.
    Berestizschevsky S, Weinberger D, Avisar I, Avisar R. Episcleritis associated with familial Mediterranean fever. Isr Med Assoc J 10(4):318–319Google Scholar
  43. 43.
    Cantarini L, Vitale A, Scalini P, Dinarello CA, Rigante D, Franceschini R et al (2015) Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol 34(7):1293–1301. CrossRefPubMedGoogle Scholar
  44. 44.
    Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S (2012) Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis 71(9):1589–1591. CrossRefPubMedGoogle Scholar
  45. 45.
    Fabiani C, Vitale A, Emmi G, Lopalco G, Vannozzi L, Guerriero S et al (2017) Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36(1):191–197. CrossRefPubMedGoogle Scholar
  46. 46.
    Brambilla A, Caputo R, Cimaz R, Simonini G (2016) Canakinumab for childhood sightthreatening refractory uveitis: a case series. J Rheumatol 43(7):1445–1447. CrossRefPubMedGoogle Scholar
  47. 47.
    Hirano M, Seguchi J, Yamamura M, Narita A, Okanobu H, Nishikomori R et al (2015) Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study. J Ophthalmic Inflamm Infect 5(1):34. CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Simonini G, Xu Z, Caputo R, De Libero C, Pagnini I, Pascual V et al (2013) Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. ArthritisRheum 65(2):513–518. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pediatric Nephrology DepartmentAnkara Dr. Sami Ulus Maternity and Children HospitalAnkaraTurkey
  2. 2.Pediatric Nephrology and Rheumatology DepartmentOndokuz Mayıs UniversitySamsunTurkey
  3. 3.Pediatric Nephrology Department, Medical SchoolYildirim Beyazit UniversityAnkaraTurkey
  4. 4.Pediatric Nephrology and Rheumatology DepartmentAnkara Dr. Sami Ulus Maternity and Children HospitalAnkaraTurkey

Personalised recommendations